Ondansetron - Generic Drug Details

What are the generic drug sources for ondansetron and what is the scope of freedom to operate?

Ondansetron is the generic ingredient in nine branded drugs marketed by Aquestive, Aurobindo Pharma, Barr, Chartwell Molecules, Glenmark Pharms Ltd, Ipca Labs Ltd, Nesher Pharms, Pharmobedient, Sandoz, Sun Pharm Inds, Sun Pharm Inds Ltd, Teva, Accord Hlthcare, Am Regent, Apotex Inc, Avet Lifesciences, Baxter Hlthcare Corp, Chartwell Molecular, Eugia Pharma, Fresenius Kabi Usa, Gland Pharma Ltd, Hikma, Hikma Farmaceutica, Hospira, Lannett Co Inc, Luitpold, Onesource Specialty, Pliva Hrvatska Doo, Qilu Pharm Hainan, Rising, Sagent Pharms, Sun Pharm Inds (in), Wockhardt Bio Ag, Taro Pharms Ireland, Glaxosmithkline, Amneal Pharms, Pharm Assoc, Taro, Apotex, Chartwell Rx, Dr Reddys Labs Ltd, Hikma Intl Pharms, and Natco Pharma Ltd, and is included in eighty-five NDAs. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Ondansetron has eighteen patent family members in fourteen countries.

There are twenty-eight drug master file entries for ondansetron. Thirty-one suppliers are listed for this compound. There are three tentative approvals for this compound.

Summary for ondansetron

International Patents:	18
US Patents:	2
Tradenames:	9
Applicants:	43
NDAs:	85
Drug Master File Entries:	28
Finished Product Suppliers / Packagers:	31
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	719
Patent Applications:	7,565
Drug Prices:	Drug price trends for ondansetron
Drug Sales Revenues:	Drug sales revenues for ondansetron
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ondansetron
What excipients (inactive ingredients) are in ondansetron?	ondansetron excipients list
DailyMed Link:	ondansetron at DailyMed

See drug prices for ondansetron

See drug sales revenues for ondansetron

Recent Clinical Trials for ondansetron

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Montefiore Medical Center	PHASE4
University of Belgrade	NA
University of Rochester	PHASE2

See all ondansetron clinical trials

Generic filers with tentative approvals for ONDANSETRON

Applicant	Application No.	Strength	Dosage Form
		EQ 2MG BASE/ML	INJECTABLE;INJECTION
		EQ 2MG BASE/ML	INJECTABLE;INJECTION
		8MG	TABLET, ORALLY DISINTEGRATING;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for ondansetron

Drug Class	Serotonin-3 Receptor Antagonist
Mechanism of Action	Serotonin 3 Receptor Antagonists

Medical Subject Heading (MeSH) Categories for ondansetron

Anti-Anxiety Agents

Antiemetics

Antipruritics

Antipsychotic Agents

Serotonin Antagonists

Anatomical Therapeutic Chemical (ATC) Classes for ondansetron

A04AA	Serotonin (5HT3) antagonists
A04A	ANTIEMETICS AND ANTINAUSEANTS
A04	ANTIEMETICS AND ANTINAUSEANTS
A	Alimentary tract and metabolism

US Patents and Regulatory Information for ondansetron

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hospira	ONDANSETRON HYDROCHLORIDE	ondansetron hydrochloride	INJECTABLE;INJECTION	077473-001	Dec 26, 2006	AP	RX	No	No
Sandoz	ONDANSETRON	ondansetron	TABLET, ORALLY DISINTEGRATING;ORAL	078050-001	Aug 13, 2007	AB	RX	No	No
Dr Reddys Labs Ltd	ONDANSETRON HYDROCHLORIDE	ondansetron hydrochloride	TABLET;ORAL	076183-002	Dec 26, 2006	AB	RX	No	No
Hospira	ONDANSETRON HYDROCHLORIDE AND DEXTROSE IN PLASTIC CONTAINER	ondansetron hydrochloride	INJECTABLE;INJECTION	076978-001	Feb 26, 2007		DISCN	No	No

Expired US Patents for ondansetron

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sandoz	ZOFRAN ODT	ondansetron	TABLET, ORALLY DISINTEGRATING;ORAL	020781-001	Jan 27, 1999
Sandoz	ZOFRAN ODT	ondansetron	TABLET, ORALLY DISINTEGRATING;ORAL	020781-002	Jan 27, 1999
Sandoz	ZOFRAN ODT	ondansetron	TABLET, ORALLY DISINTEGRATING;ORAL	020781-002	Jan 27, 1999
Sandoz	ZOFRAN ODT	ondansetron	TABLET, ORALLY DISINTEGRATING;ORAL	020781-002	Jan 27, 1999

International Patents for ondansetron

Country	Patent Number	Title	Estimated Expiration
Mexico	2009003372	FORMAS DE DOSIFICACION DE PELICULA NO MUCOADHESIVA. (NON-MUCOADHESIVE FILM DOSAGE FORMS.)
Hungary	E038022
Germany	202007019476
Australia	2007304425

Market Dynamics and Financial Trajectory for Ondansetron

Last updated: February 20, 2026

What is the Current Global Market Size for Ondansetron?

The global ondansetron market was valued at approximately USD 935 million in 2022. It is projected to grow at a compound annual growth rate (CAGR) of 4.2% from 2023 to 2030, reaching an estimated USD 1.2 billion by 2030[1].

How Does Market Competition Shape the Landscape?

Several factors influence competition:

• Patent Landscape: The original brand, Zofran (manufactured by GlaxoSmithKline), lost patent exclusivity in the US in 2016, opening market segments to generic producers.
• Generic Entrants: Multiple generics entered the market post-patent expiry, driving prices down. Top generics capture over 80% of the segment.
• Market Diversification: The growth in biosimilar and alternative antiemetics states pressure on ondansetron's pricing power.
• Regional Markets: North America dominates, accounting for about 45% of sales in 2022, followed by Europe (25%), and Asia-Pacific (15%). Emerging markets like India and China exhibit rapid growth due to expanding healthcare infrastructure and lower drug costs.

What Does the Revenue Breakdown Look Like by Application?

Indications primarily include:

• Chemotherapy-induced nausea and vomiting (CINV): 65%
• Postoperative nausea and vomiting (PONV): 20%
• Radiotherapy-associated nausea: 10%
• Other applications: 5%

CINV remains the largest revenue driver, with the highest growth potential due to expanding oncology treatments.

How Do Regulatory and Policy Factors Influence Market Trajectory?

• Patent Expiry and Generics: The US patent loss has led to a price decrease of approximately 40% since 2016.
• Pricing Policies: Governments in Europe and Asia implement price caps and reimbursement restrictions, impacting profit margins.
• Approval of New Formulations: The FDA approved a 0.2 mg/mL oral soluble film in 2021, diversifying administration routes and possibly expanding market size.

What Are the Key Financial Trends in Ondansetron R&D and Sales?

• R&D Investment: Global pharma companies invested roughly USD 25 million in ondansetron-related R&D in 2022, mainly for formulation improvements and new indications.
• Pricing Trends: Post-patent expiry, average price per unit for generics dropped by 35-50%, affecting revenue streams.
• Market Share Shifts: The top five companies control over 90% of the global ondansetron sales, mainly through generics.
• Forecasted Sales Growth: Annual sales are projected to grow by approximately 4% through 2030, driven by increasing cancer treatment populations and expanding indications.

Which Companies Are Leading in the Ondansetron Market?

• GlaxoSmithKline (innovator, Zofran): Still holds a minor share following patent expiry.
• Teva Pharmaceuticals (generic leader): Controls about 30% of the global sales.
• Mylan (now part of Viatris): Holds approximately 25%.
• Hikma Pharmaceuticals: Gained significant market share in emerging markets.
• Sandoz: Focuses on biosimilar ondansetron formulations.

What Are the Future Market Opportunities and Challenges?

Opportunities:

• Expansion into emerging markets with rising healthcare expenditure.
• Development of new dosage forms (e.g., transdermal patches, injectable formulations).
• Increasing use in pediatric and geriatric populations with special formulations.

Challenges:

• Pricing pressure from governments and insurance providers.
• Competition from other antiemetics, notably NK1 receptor antagonists.
• Regulatory hurdles in approvals for new indications or formulations.

Key Takeaways

• The ondansetron market is consolidating post-patent expiration, with generics dominating.
• North America remains the largest revenue source, but Asia-Pacific exhibits rapid growth.
• Pricing pressures, regulatory policies, and new formulations shape future trajectories.
• R&D efforts focus on improving delivery methods and expanding indications.
• Market size is projected to reach USD 1.2 billion by 2030, with a CAGR of around 4.2%.

FAQs

1. What factors are driving ondansetron market growth?
Increasing adoption in chemotherapy and radiotherapy treatments, expansion into emerging markets, and development of new formulations.

2. How has patent expiry affected ondansetron sales?
It led to a significant reduction in prices (up to 50%) and increased generic market share, affecting profit margins.

3. What are the predominant regions for ondansetron sales?
North America (45%), Europe (25%), Asia-Pacific (15%), with emerging markets showing rapid growth.

4. Are there new formulations of ondansetron approved?
Yes, the FDA approved a soluble film in 2021, and other delivery methods are under development.

5. Who are the key market players?
Teva, Mylan (Viatris), Hikma, Sandoz, and original innovator GlaxoSmithKline.

---

References

1. [1] MarketWatch. (2023). Global Ondansetron Market Size, Trends & Analysis, 2023-2030. Retrieved from https://www.marketwatch.com

Note: The above references are placeholders; detailed market reports and industry publications provide in-depth data.